Navigation Links
ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay(TM)
Date:3/8/2010

IRVINE, Calif., March 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).  The FDA has granted XiDay a standard review time of ten months, assigning ISTA a Prescription Drug User Fee Act (PDUFA) action date of October 16, 2010.  ISTA's request for a shorter, six-month priority review is still under consideration by the FDA.

Xibrom™ (bromfenac ophthalmic solution)

ISTA currently markets Xibrom (bromfenac ophth
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... quarter ended March 28, 2015. Net sales ... an increase of 1.4% compared with the first quarter ... currencies and a 6.0% decline related to foreign currency ...
(Date:5/4/2015)... MONMOUTH JUNCTION, N.J. , May 4, 2015 ... critical care immunotherapy company commercializing its CytoSorb® extracorporeal ... patients in multiple countries worldwide, will report Q1 ... Monday, May 11, 2015.  CytoSorbents, ... presentation webcast that will recount both operational and ...
(Date:5/4/2015)... Utah , May 4, 2015 ... a manufacturer and marketer of rehabilitation and physical ... into definitive agreements to raise approximately $4,000,000 in ... LLC and certain of its affiliates (together with ... focused on the healthcare industry. The financing will ...
Breaking Medicine Technology:Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4
... Demonstrates Impressive Single Agent Efficacy in Patients who Progressed ... or after Treatment with both a VEGF Receptor Inhibitor ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) ... (perifosine), the Company,s Akt-inhibitor for cancer, as a treatment ...
... 29 Spirus Medical, Inc. ( www.spirusmed.com ... therapeutic advancement systems for gastroenterology, urology and gynecology, ... devices have performed complete examinations of the small ... Digestive Disease Week 2009 in Chicago, May 30 ...
Cached Medicine Technology:Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer 2Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer 3Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer 4Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer 5Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM) 2
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... METTLER TOLEDO has announced an upcoming ... in a GXP Regulated Laboratory ", featuring independent ... will be presented on May 27, 2015 at ... a critical component of pharmaceutical product quality and ... recent years an increasing number of inspections have ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... 04, 2015 CCL, a top-ranked, global ... unique program to other leadership development consultancies. “The ... CCL and successful practitioners, expanding our capacity to drive ... said John R. Ryan, CCL President and CEO. , ... CCL Partner Network , it will schedule a one-on-one ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2
... LOS ANGELES, March 5 With the nation focused ... Valley) recently announced Assembly Bill 562 ( ... to businesses and consumers that have fallen victim to ... decreases health care premium costs. It requires insurance companies ...
... YORK, March 5 An article published in the ... , a joint publication of United Spinal Association ( ... Multiple Sclerosis (NARCOMS), reveals the importance of understanding ... it can also lead to a greater understanding and ...
... day for six months were able to increase the flaccid ... erectile function by up to 36%, according to an independent ... International . , Researchers from San Giovanni Battista Hospital at ... treatment could provide a viable alternative to surgery, as the ...
... Sick or injured African-American patients wait about an ... being transferred to an inpatient hospital bed following ... study published in the journal Academic Emergency ... the urgency to find equitable, cost-effective solutions to ...
... Already Breaking down Silos and Benefiting from Paperless ... Waters Corporation (NYSE: WAT ) ... strategic partnership to integrate laboratory software for improved ... Collaborating with existing common customers, Waters(R) and LabVantage(R) ...
... Texas and SAN FRANCISCO, March 5 Preferred ... payment and transaction-processing services for the health care ... ), the world,s largest retail payments network, today ... brand for PHT,s A-Claim(TM) medical payment solution for ...
Cached Medicine News:Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:United Spinal Association Report Reveals the Importance of Studying Multiple Sclerosis in Children: Developing New Insights into MS in Adults 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 4Health News:Preferred Health Technology and Visa Inc. Team Up on Comprehensive Point-of-Service Medical Payments Solution 2Health News:Preferred Health Technology and Visa Inc. Team Up on Comprehensive Point-of-Service Medical Payments Solution 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: